Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial (Nature Medicine, (2022), 28, 10, (2155-2161), 10.1038/s41591-022-01962-5)

LCMC study investigators; Jamie E. Chaft; Filiz Oezkan; Mark G. Kris; Paul A. Bunn; Ignacio I. Wistuba; David J. Kwiatkowski; Dwight H. Owen; Yan Tang; Bruce E. Johnson; Jay M. Lee; Gerard Lozanski; Maciej Pietrzak; Michal Seweryn; Woo Yul Byun; Katja Schulze; Alan Nicholas; Ann Johnson; Jessica Grindheim; Stephanie Hilz; David S. Shames; Chris Rivard; Eric Toloza; Eric B. Haura; Ciaran J. McNamee; G. Alexander Patterson; Saiama N. Waqar; Valerie W. Rusch; David P. Carbone; Saiama N. Waqar; Elaine Shum; Misako Nagasaka; Marianna Koczywas; Edward B. Garon; David J. Finley; David R. Camidge; Jennifer W. Carlisle; Justin D. Blasberg

doi:10.1038/s41591-023-02627-7

Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial (Nature Medicine, (2022), 28, 10, (2155-2161), 10.1038/s41591-022-01962-5)

LCMC study investigators, Jamie E. Chaft, Filiz Oezkan, Mark G. Kris, Paul A. Bunn, Ignacio I. Wistuba, David J. Kwiatkowski, Dwight H. Owen, Yan Tang, Bruce E. Johnson, Jay M. Lee, Gerard Lozanski, Maciej Pietrzak, Michal Seweryn, Woo Yul Byun, Katja Schulze, Alan Nicholas, Ann Johnson, Jessica Grindheim, Stephanie HilzDavid S. Shames, Chris Rivard, Eric Toloza, Eric B. Haura, Ciaran J. McNamee, G. Alexander Patterson, Saiama N. Waqar, Valerie W. Rusch, David P. Carbone, Saiama N. Waqar, Elaine Shum, Misako Nagasaka, Marianna Koczywas, Edward B. Garon, David J. Finley, David R. Camidge, Jennifer W. Carlisle, Justin D. Blasberg

Research output: Contribution to journal › Comment/debate

2 Scopus citations

Abstract

Correction to: Nature Medicine. Published online 12 September 2022. In the version of this article initially published, the first sentence of the Fig. 4a caption (now reading “The expression of different NK cell surface receptors was determined by scRNA-seq”) was incorrectly preceded by the text “Association between gene expression in NK cells and the percentage of viable tumor cells,” which has now been removed from the HTML and PDF versions of the article.

Original language	English
Pages (from-to)	303
Number of pages	1
Journal	Nature medicine
Volume	30
Issue number	1
DOIs	https://doi.org/10.1038/s41591-023-02627-7
State	Published - Jan 2024

Access to Document

10.1038/s41591-023-02627-7

Cite this

LCMC study investigators, Chaft, J. E., Oezkan, F., Kris, M. G., Bunn, P. A., Wistuba, I. I., Kwiatkowski, D. J., Owen, D. H., Tang, Y., Johnson, B. E., Lee, J. M., Lozanski, G., Pietrzak, M., Seweryn, M., Byun, W. Y., Schulze, K., Nicholas, A., Johnson, A., Grindheim, J., ... Blasberg, J. D. (2024). Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial (Nature Medicine, (2022), 28, 10, (2155-2161), 10.1038/s41591-022-01962-5). Nature medicine, 30(1), 303. https://doi.org/10.1038/s41591-023-02627-7

@article{e2290a01fb2d47928ef5ecdad4f1a426,

title = "Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial (Nature Medicine, (2022), 28, 10, (2155-2161), 10.1038/s41591-022-01962-5)",

abstract = "Correction to: Nature Medicine. Published online 12 September 2022. In the version of this article initially published, the first sentence of the Fig. 4a caption (now reading “The expression of different NK cell surface receptors was determined by scRNA-seq”) was incorrectly preceded by the text “Association between gene expression in NK cells and the percentage of viable tumor cells,” which has now been removed from the HTML and PDF versions of the article.",

author = "{LCMC study investigators} and Chaft, {Jamie E.} and Filiz Oezkan and Kris, {Mark G.} and Bunn, {Paul A.} and Wistuba, {Ignacio I.} and Kwiatkowski, {David J.} and Owen, {Dwight H.} and Yan Tang and Johnson, {Bruce E.} and Lee, {Jay M.} and Gerard Lozanski and Maciej Pietrzak and Michal Seweryn and Byun, {Woo Yul} and Katja Schulze and Alan Nicholas and Ann Johnson and Jessica Grindheim and Stephanie Hilz and Shames, {David S.} and Chris Rivard and Eric Toloza and Haura, {Eric B.} and McNamee, {Ciaran J.} and Patterson, {G. Alexander} and Waqar, {Saiama N.} and Rusch, {Valerie W.} and Carbone, {David P.} and Waqar, {Saiama N.} and Elaine Shum and Misako Nagasaka and Marianna Koczywas and Garon, {Edward B.} and Finley, {David J.} and Camidge, {David R.} and Carlisle, {Jennifer W.} and Blasberg, {Justin D.}",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2024",

month = jan,

doi = "10.1038/s41591-023-02627-7",

language = "English",

volume = "30",

pages = "303",

journal = "Nature medicine",

issn = "1078-8956",

number = "1",

}

LCMC study investigators, Chaft, JE, Oezkan, F, Kris, MG, Bunn, PA, Wistuba, II, Kwiatkowski, DJ, Owen, DH, Tang, Y, Johnson, BE, Lee, JM, Lozanski, G, Pietrzak, M, Seweryn, M, Byun, WY, Schulze, K, Nicholas, A, Johnson, A, Grindheim, J, Hilz, S, Shames, DS, Rivard, C, Toloza, E, Haura, EB, McNamee, CJ, Patterson, GA , Waqar, SN, Rusch, VW, Carbone, DP, Waqar, SN, Shum, E, Nagasaka, M, Koczywas, M, Garon, EB, Finley, DJ, Camidge, DR, Carlisle, JW & Blasberg, JD 2024, 'Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial (Nature Medicine, (2022), 28, 10, (2155-2161), 10.1038/s41591-022-01962-5)', Nature medicine, vol. 30, no. 1, pp. 303. https://doi.org/10.1038/s41591-023-02627-7

Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial (Nature Medicine, (2022), 28, 10, (2155-2161), 10.1038/s41591-022-01962-5). / LCMC study investigators; Chaft, Jamie E.; Oezkan, Filiz et al.
In: Nature medicine, Vol. 30, No. 1, 01.2024, p. 303.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Author Correction

T2 - Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial (Nature Medicine, (2022), 28, 10, (2155-2161), 10.1038/s41591-022-01962-5)

AU - LCMC study investigators

AU - Chaft, Jamie E.

AU - Oezkan, Filiz

AU - Kris, Mark G.

AU - Bunn, Paul A.

AU - Wistuba, Ignacio I.

AU - Kwiatkowski, David J.

AU - Owen, Dwight H.

AU - Tang, Yan

AU - Johnson, Bruce E.

AU - Lee, Jay M.

AU - Lozanski, Gerard

AU - Pietrzak, Maciej

AU - Seweryn, Michal

AU - Byun, Woo Yul

AU - Schulze, Katja

AU - Nicholas, Alan

AU - Johnson, Ann

AU - Grindheim, Jessica

AU - Hilz, Stephanie

AU - Shames, David S.

AU - Rivard, Chris

AU - Toloza, Eric

AU - Haura, Eric B.

AU - McNamee, Ciaran J.

AU - Patterson, G. Alexander

AU - Waqar, Saiama N.

AU - Rusch, Valerie W.

AU - Carbone, David P.

AU - Waqar, Saiama N.

AU - Shum, Elaine

AU - Nagasaka, Misako

AU - Koczywas, Marianna

AU - Garon, Edward B.

AU - Finley, David J.

AU - Camidge, David R.

AU - Carlisle, Jennifer W.

AU - Blasberg, Justin D.

PY - 2024/1

Y1 - 2024/1

N2 - Correction to: Nature Medicine. Published online 12 September 2022. In the version of this article initially published, the first sentence of the Fig. 4a caption (now reading “The expression of different NK cell surface receptors was determined by scRNA-seq”) was incorrectly preceded by the text “Association between gene expression in NK cells and the percentage of viable tumor cells,” which has now been removed from the HTML and PDF versions of the article.

AB - Correction to: Nature Medicine. Published online 12 September 2022. In the version of this article initially published, the first sentence of the Fig. 4a caption (now reading “The expression of different NK cell surface receptors was determined by scRNA-seq”) was incorrectly preceded by the text “Association between gene expression in NK cells and the percentage of viable tumor cells,” which has now been removed from the HTML and PDF versions of the article.

UR - http://www.scopus.com/inward/record.url?scp=85173826880&partnerID=8YFLogxK

U2 - 10.1038/s41591-023-02627-7

DO - 10.1038/s41591-023-02627-7

M3 - Comment/debate

C2 - 37816821

AN - SCOPUS:85173826880

SN - 1078-8956

VL - 30

SP - 303

JO - Nature medicine

JF - Nature medicine

IS - 1

ER -

Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial (Nature Medicine, (2022), 28, 10, (2155-2161), 10.1038/s41591-022-01962-5)

Abstract

Access to Document

Other files and links

Fingerprint

Cite this